India’s first COVID-19 immunization ‘COVAXIN’ by Bharat Biotech gets DCGI endorsement for human trial Kumar Jeetendra | June 30, 2020 India’s very first vaccine candidate against the novel coronavirus, COVAXIN, has received a nod in the Drug Controller General of India (DCGI) for further clinical trials Stage I and two in infected men and women. The vaccine is under development by Hyderbad-based biotechnology firm Bharat Biotech in cooperation with the Indian Council of Medical Research …
ICMR affirms Covaxin dispatch likely by August 15, clinical preliminaries optimized Kumar Jeetendra | July 3, 2020 An ICMR representative has affirmed the credibility of a letter by ICMR Head that said the antibody preliminaries for Hyderabad-based Bharat Biotech’s COVID-19 immunization Covaxin have been optimized and that it could be propelled most recent by August 15. ICMR had on July 2 purportedly asked Bharat Biotech in an inner correspondence to quick track …
COVID-19 immunization dispatch by Aug 15 unfeasible, ICMR pummeled for raising ‘unreasonable expectation and desires’ Kumar Jeetendra | July 5, 2020 Terming it”unfeasible”, the Indian Academy of Sciences (IASc) slammed in the Indian Council of Medical Research (ICMR) on July 5 to its claims that an native vaccine contrary to the novel coronavirus will be started by August 15, following completion of clinical trials. Both are collectively developing a disease against SARS-CoV-2the virus that causes COVID-19. …
Clinical preliminary of COVID-19 Covaxin vaccine starts at NIMS Hyderabad Kumar Jeetendra | July 8, 2020 ICMR’s National Institute of Virology and Bharat Biotech are jointly developing a vaccine against SARS-CoV-2the virus that causes COVID-19. “We will select healthy individuals and draw blood and send the blood samples to designated labs in New Delhi. They will give the green signal. Then the medicine people will examine and the first shot of …
Preparations on for next phase of clinical trial of’Covaxin’ vaccine Kumar Jeetendra | August 31, 2020 Preparations are underway in a hospital here for the commencement of the second stage of human clinical trial of’Covaxin’,” India’s indigenous COVID-19 vaccine, officials said. “The Phase I of the trial is still continuing as we are planning for the beginning of the Stage II trial soon,” Dr E Venkata Rao, Principal Investigator of the …
Bharat Biotech States Covaxin generated Strong immune response in monkeys Kumar Jeetendra | September 12, 2020 Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus. The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate. Covaxin developed …
Covid immunization: Bharat Biotech to utilize ViroVax’s adjuvant for Covaxin Kumar Jeetendra | October 5, 2020 Trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity. The technology has been used under this licensing arrangement with US-based ViroVax. Adjuvant is used to boost the vaccine efficacy. Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated in the National Institute of Virology (NIV), Pune under …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
India sees early vaccine dispatch as AstraZeneca conveyances run late Kumar Jeetendra | November 6, 2020 A vaccine is seen as the world’s best bet for taming a virus that has infected more than 48 million people, led to over 1.2 million deaths, roiled markets and disrupted countless lives because it was first identified in China in December. Australia is beefing up its potential arsenal against the pandemic to 135 million …
Emergency use SEC approval for Bharat Biotech Covaxin Kumar Jeetendra | January 2, 2021 The SEC has recommended Covaxin for emergency use authorisation (EUA), reported news agency ANI quoting government sources. The recommendation, together with rollout modalities, will be taken up from the Drug Controller General of India (DCGI) to get a final decision on the issue. The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) …
Brazil probes Health Ministry arrangement to purchase Covaxin vaccine Kumar Jeetendra | June 23, 2021 Brazil’s federal prosecutor’s office is investigating possible irregularities in a Health Ministry contract to purchase 20 million doses of the Covaxin vaccine manufactured by Indian laboratory Bharat Biotech. The agreement signed in February commits the ministry to pay USD 320 million – at a cost of USD 15 per vaccine dose – to Precisa Medicamentos, …
Bharat Biotech’s partner Ocugen looks for endorsement for Covaxin in Canada Kumar Jeetendra | July 16, 2021 Ocugen Inc., Bharat Biotech’s partner for USA and Canada for COVID-19 vaccine Covaxin has initiated a rolling submission to Health Canada for the jab, the US company said in a regulatory filing. The move follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults, …